Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

1. A polysaccharide of formula (I):

in which:

the wavy line denotes a bond situated either below or above the plane of the pyranose ring,

the formula (Po):

 denotes a polysaccharide, comprising n identical or different monosaccharide u its, bonded via its anomeric carbon to Pe, in which the formula:

 represents a monosaccharide unit with a pyranose structure chosen from hexoses, pentoses and the corresponding deoxy sugars, this unit being bonded via its anomeric carbon to another monosaccharide unit and the hydroxyl groups of this unit being substituted by identical or different R 1 groups,

Pe represents a pentasaccharide of structure:

h is 1 or 2,

n is an integer from 0 to 25,

R 1 represents the —T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents the —T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents the —T-Biot linkage or a (C 1 -C 6 )alkoxy group,

R 4 represents the —T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 — bridge, the —CH 2 — group being bonded to the car on atom carrying the carboxyl functional group on the same ring; at least one of the R 1 , R 2 , R 3 or R 4 substituents represents a —T-Biot group,

W represents an oxygen atom or a methylene group,

T represents one of the linkages chosen from:

NH,

 in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

or a pharmaceutically acceptable salt thereof.

2. A polysaccharide according to claim 1 of formula (I.1):

denotes polysaccharides Po which are bonded via their anomeric carbon to Pe

m is an integer varying from 1 to 5, t is an integer varying from 0 to 24 and p is an integer varying from 0 to 24, it being understood that 1≦m+t+p≦25, or

a pharmaceutically acceptable salt thereof.

3. A polysaccharide according to claim 2 wherein only one of the R 1 , R 2 , R 3 or R 4 substituents represents the —T-Biot linkage.

4. A hexadecasaccharide according to claim 3 of formula (I.2):

in which:

T is chosen from:

NH,

 in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

Pe represents a pentasaccharide of structure:

 in which:

R 1 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents a (C 1 -C 6 )alkoxy group,

R 4 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 — bridge, the —CH 2 group being bonded to the carbon atom carrying the carboxyl functional group on the same ring,

W represents an oxygen atom or a methylene group, or

a pharmaceutically acceptable salt thereof.

5. A pentasaccharide according to claim 1 of formula (I.3):

or a pharmaceutically acceptable salt thereof.

6. A pentasaccharide according to claim 5 wherein only one of the R 1 , R 2 , R 3 or R 4 substituents represents the —T-Biot linkage.

7. A pentasaccharide according to claim 6 of formula (I.4):

in which:

T is chosen from:

NH,

 in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

R 1 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents a (C 1 -C 6 )alkoxy group,

R 4 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 — bridge, the —CH 2 — group being bonded to the carbon atom carrying the carboxyl functional group on the same ring,

W represents an oxygen atom or a methylene group, or

a pharmaceutically acceptable salt thereof.

8. A polysaccharide according to claim 1 chosen from:

Methyl(2,3,4,6-tetra-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6-biotinamido-6-deoxy-2,3-di-O-methyl-α-D-glucopyranosyl)(1→4)-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-[(2,3,6-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-O-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O-sulphonato-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl(2,3,4,6-tetra-O-sulphonato-α-D-glucopyranosyl-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6-[6-(biotinamido)hexamido]-6-deoxy-2,3-di-O-methyl-α-D-glucopyranosyl-(1→4)-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-[(2,3,6-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-O-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O-sulphonato-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl(2,3,4,6-tetra-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6-[6-(6-biotinamido-hexamido)hexamido]-6-deoxy-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-[(2,3,6-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-O-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O-sulphonato-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl(2-biotinamido-2-deoxy-3,4-di-O-methyl-6-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside sodium salt,

Methyl(2-[6-(6-biotinamidohexamido)hexamido]-2-deoxy-3,4-di-O-methyl-6-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt, and

Methyl(2-[6-(6-biotinamidohexamido)hexamido]-2-deoxy-3,4-di-O-methyl-6-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt.

9. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising a compound according to claim 4 together with a pharmaceutically acceptable excipient.

11. A pharmaceutical composition comprising a compound according to claim 5 together with a pharmaceutically acceptable excipient.

12. A pharmaceutical composition comprising a compound according to claim 7 together with a pharmaceutically acceptable excipient.

13. A pharmaceutical composition comprising a compound according to claim 8 together with a pharmaceutically acceptable excipient.

14. A method for neutralizing the antithrombotic effect of the compounds according to claim 1 in a patient which comprises administering to said patient an effective amount of avidin or streptavidin.

15. A method for neutralizing the antithrombotic effect of the compounds according to claim 8 in a patient which comprises administering o said patient an effective amount of avidin or streptavidin.